Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why Moderna (MRNA) Fell More Than Broader Market

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $26.68, moving 2.45% from the previous trading session.

Zacks Equity Research

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

by Zacks Equity Research

NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.

Kinjel Shah headshot

Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE?

by Kinjel Shah

MRK leans on Keytruda for growth as exclusivity loss nears, with new combos and launches aiming to ease reliance.

Zacks Equity Research

Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?

by Zacks Equity Research

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike

by Zacks Equity Research

MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.

Zacks Equity Research

Company News for Jun 3, 2025

by Zacks Equity Research

Companies in The News Are: CPB,SAIC,MRNA,GM

Kinjel Shah headshot

Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates

by Kinjel Shah

LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine funding, while SNY sees mixed COPD data.

Zacks Equity Research

U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot

by Zacks Equity Research

The government scraps funding deal for MRNA's bird flu shot, despite encouraging safety and efficacy data from early clinical studies on the vaccine.